日韩国产91,91麻豆精品成人一区二区,精品国产av一二三四区

Novo Nordisk H1 2025 Financial Reports Financial statements Novo Nordisk Semaglutide Novo Nordisk's Semaglutide generated $16.7B in H1 2025, surpassing Keytruda as the world's top-selling drug. Strong global and China sales drive growth despite competitive challenges.
Global Biopharma Layoffs August 2025 Layoffs Layoff Merck Moderna Bayer Pfizer The biopharmaceutical industry sees major August layoffs, with companies like Moderna, Merck cutting jobs amid restructurings, trial setbacks, and M&A activity.
Pfizer 2025 H1 Report Financial statements Pfizer Pfizer reported $28.4B in revenue for H1 2025, driven by $1.5B in ADC product sales and strong oncology growth. With $13B in BD firepower, Pfizer eyes long-term expansion across key therapeutic areas.
Small RNA Giant 2025 H1: RNAi Products Sold 8.2 Billion! Alnylam Pharmaceuticals Financial statements Alnylam reports strong 2025 H1 results with $1.14B in RNAi drug sales, up 47% YoY. AMVUTTRA drives growth; stock jumps 15% as market cap surpasses $50B. Pipeline advances in Alzheimer’s, diabetes, and hypertension.
Original Drugs? Generic Drugs? Patent Drugs? Explained in One Article Original Drugs Generic Drugs Patent Drugs Market Trend Learn the key differences between patent, original, and generic drugs. Understand their development, pricing, quality, and how to choose the right medication for safety, affordability, and effectiveness.
AbbVie's Bold Claim: To Become the Largest CNS Company Next Year! AbbVie Market Trend AbbVie sets its sights on becoming the top CNS company by 2026, driven by strong H1 growth, strategic acquisitions, and breakthrough treatments in neuroscience, including schizophrenia, migraine, and Parkinson’s disease.
Pfizer Secures Global Rights to SSGJ-707: A Next-Gen PD-1/VEGF Bispecific for Cancer Treatment Pfizer Market Trend ASCO Cancer Pfizer acquires global rights to SSGJ-707, a PD-1/VEGF bispecific antibody from 3SBio, aiming to enhance its oncology pipeline with a novel mechanism and strong clinical potential.
AstraZeneca 2025 H1 Results AstraZeneca Financial statements AstraZeneca reports strong H1 2025 results with $28B in revenue. Oncology leads growth, driven by Enhertu, Tagrisso, and Truqap. R&D up 16%. Strong gains in CVRM, R&I, and rare diseases.
AbbVie 2025 H1 Report AbbVie Financial statements AbbVie reports strong H1 2025 results with $28.77B in revenue, driven by autoimmune leaders Skyrizi and Rinvoq. Oncology and neuroscience segments also show solid growth and strategic expansions.
GSK 2025 H1 Performance GSK Financial statements GSK reports strong H1 2025 results with ￡15.5B revenue. Oncology grows 47%, HIV remains robust, and vaccines stay steady. Company targets ￡40B+ annual sales by 2031.